Table 3. Association of the TP53 Arg72Propolymorphism with breast cancer risk in the indicated subgroups.
| Category | No. of cases (%) | Pro/Pro vs. Arg/Arg | Arg/Pro vs. Arg/Arg | Pro vs. Arg | ||||
| OR | 95% CI | OR | 95% CI | OR | 95% CI | |||
| Age (years)1 | <55 | 106 (39.7%) | 2.10 | (0.73–6.10) | 1.30 | (0.80–2.10) | 1.36 | (0.92–2.02) |
| ≥55 | 161 (60.3%) | 2.57 | (1.00–6.58) | 1.50 | (0.98–2.28) | 1.54 | (1.09–2.18)* | |
| Tumor type | ductal | 148 (75.9%) | 1.90 | (0.70–5.14) | 1.26 | (0.82–1.94) | 1.31 | (0.92–1.87) |
| lobular | 47 (24.1%) | 4.34 | (1.28–14.7)* | 1.92 | (0.98–3.74) | 2.01 | (1.20–3.37)** | |
| Grade | pG1-2 | 157 (64.1%) | 3.08 | (1.21–7.80)* | 1.70 | (1.11–2.60)* | 1.72 | (1.22–2.44)** |
| pG3 | 88 (35.9%) | 1.59 | (0.50–5.11) | 1.00 | (0.60–1.67) | 1.10 | (0.72–1.68) | |
| p53 status | pos | 56 (22.7%) | 1.62 | (0.40–6.47) | 1.19 | (0.65–2.18) | 1.22 | (0.74–2.02) |
| neg | 191 (77.3%) | 2.76 | (1.12–6.79)* | 1.54 | (1.03–2.30)* | 1.59 | (1.14–2.21)** | |
| ER status | pos | 196 (77.2%) | 2.73 | (1.11–6.71)* | 1.59 | (1.06–2.37)* | 1.61 | (1.16–2.24)** |
| neg | 58 (22.8%) | 2.08 | (0.59–7.38) | 1.15 | (0.63–2.10) | 1.27 | (0.78–2.07) | |
| PR status | pos | 137 (53.9%) | 3.07 | (1.17–8.05)* | 1.80 | (1.15–2.08)* | 1.78 | (1.24–2.55)** |
| neg | 117 (46.1%) | 2.08 | (0.75–5.82) | 1.17 | (0.74–1.87) | 1.28 | (0.88–1.88) | |
| HER2 status | pos | 51 (20.3%) | 2.60 | (0.80–8.53) | 0.77 | (0.39–1.49) | 1.13 | (0.68–1.88) |
| neg | 200 (79.7%) | 2.57 | (1.03–6.40)* | 1.71 | (1.15–2.54)** | 1.66 | (1.20–2.31)** | |
ER, estrogen receptor; PR, progesterone receptor; 95% CI, 95% confidence intervals.
1
patients aged under 55 years or ≥55 years at diagnosis were compared to control subjects of any age for sake of comparability with the other subgroup analyses.
*
indicates p-values <0.05; **indicates p-values <0.01.